Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

WT/Usp5-MKO PM cells were stimulated with LPS or not

ABSTRACT: Test transcripts in mock and LPS stimulated PM cells from WT or Usp5 myeloid knockout mice

ORGANISM(S): Mus musculus

PROVIDER: GSE240642 | GEO | 2024/08/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

WT/Usp5-MKO PM cells were stimulated with LPS or not

Project description:WT/Usp5-MKO PM cells were stimulated with LPS or not

| PRJNA1004543 | ENA

WT or Usp5 knockout (KO) PMs were infected with HSV-1 or not

Project description:Transcriptome profiling analysis to study deubiquitinase gene expression levels in HSV-1 infected WT or Usp5 KO PMs

2024-06-01 | GSE233795 | GEO

USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation

Project description:N6-methyladenosine (m6A) binding protein YTHDF1 is frequently upregulated in various cancers and its depletion enhances the efficacy of immune checkpoint blockade (ICB) therapy. This study reveals that USP5 interacts with YTHDF1, preventing its K11-linked polyubiquitination, thereby stabilizing YTHDF1 and promoting its oncogenic properties. In response to insulin, mTORC1 phosphorylates USP5, facilitating its dimerization and subsequent binding to YTHDF1, while the CUL7-FBXW8 complex promotes its degradation. Notably, YTHDF1 or USP5 deficiency increases PD-L1 expression and impairs immune response gene expression, contributing to immune evasion. Combining USP5 inhibitors with anti-PD-1 therapy enhances antitumor T-cell immunity and improves tumor regression in mouse models. Thus, USP5 may serve as a biomarker for stratifying patients for anti-PD-1 therapy, suggesting a novel strategy of combining USP5 inhibition with PD-(L)1 blockade to enhance cancer treatment efficacy.

2024-12-05 | GSE278264 | GEO

USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation

Project description:The N6-methyladenosine (m6A) binding protein YTHDF1 emerges as a frequently upregulated oncogene across various cancer types. Its depletion significantly improves the efficacy of cancer immune checkpoint blockade (ICB) treatment. A comprehensive understanding of the molecular mechanisms governing YTHDF1 protein stability is pivotal for enhancing clinical response rates and the effectiveness of ICB in cancer patients. Here, we report that USP5 interacts with YTHDF1, removing K11-linked polyubiquitination on multiple lysine residues to stabilize YTHDF1, thereby conferring its oncogenic properties. In response to insulin, mTORC1 phosphorylates USP5 at S149, promoting its dimerization. Dimerized USP5 then binds to YTHDF1, preventing its degradation. Conversely, the CUL7-FBXW8 E3 ubiquitin ligase promotes K11-linked polyubiquitination and degradation of YTHDF1. USP5 and FBXW8 thus regulate YTHDF1 ubiquitylation at defined residues through mutually exclusive interactions and opposing activities. Furthermore, deficiency in YTHDF1 or USP5 enhances PD-L1 expression and compromises the expression of multiple immune response-related genes, fostering cancer immune evasion. Remarkably, combining USP5 inhibitor treatment with anti-PD-1 immunotherapy reprograms the antitumor T-cell immunity environment, leading to enhanced tumor regression and markedly improved overall survival rates in mouse tumor models. Therefore, in hepatocellular carcinoma and lung cancer patients, USP5 may serve as a promising biomarker for stratifying individuals for anti-PD-1 therapy. Our findings reveal a ubiquitination-dependent regulation of YTHDF1 protein stability influencing immune response gene expression, suggesting USP5 inhibition combined with PD-(L)1 blockade as a novel and promising strategy for cancer treatment.

2024-12-11 | GSE255922 | GEO

Transcription profiling by array to investigate USP5 knock out in cardiomycytes

Project description:The experiment compares cardiomyocytes isolated from Control and USP5 KO mice 15 days after deletion by tamoxifen administration.

2024-12-14 | E-MTAB-6839 | biostudies-arrayexpress

Inhibition of USP5 offers potential targeted therapeutic strategies for t(8;21) AML through ubiquitin-mediated degradation of AML1-ETO

Project description:The AML1-ETO (AE) fusion protein is a key target for treating t(8;21) acute myeloid leukemia (AML). In this investigation, we identified ubiquitin-specific protease 5 (USP5) as the deubiquitinating enzyme of AE. USP5 knockdown decreased AML cell growth and induced differentiation both in vitro and in vivo. Additionally, we developed a high-throughput screening (HTS) method and identified a potent, selective USP5 inhibitor, WCY-8-67. This lead compound was identified as a selective USP5 inhibitor via targeting the ubiquitin-associated domain 2 (UBA2) region, and it also induced aggregation and precipitation of the target protein, leading to USP5 dysfunction. WCY-8-67 was exhibited excellent in vivo bioavailability and tolerability, and it effectively inhibited the growth of t(8;21) AML cell lines and the primary AML cells in animal models. Notably, in the patient-derived xenograft (PDX) model, this compound, when combined with 5-Azacytidine (5-Aza), demonstrated good safety and significant synergistic therapeutic effects. This study presented promising targeted therapeutic possibilities for the treatment of t(8;21) AML.

2025-09-02 | GSE306372 | GEO

Identification of PM-localized proteins

Project description:In order to assess the quality of alleged PM identifications from Arabidopsis, PM-enriched fractions were compared to PM-depleted fractions using 18O isotopic labeling and mass spectrometry. The two samples submitted are biological replicates. Keywords: Protein Localization via MS

2005-06-21 | GSE2830 | GEO

Acidiphilium sp. PM strain:PM

Project description:Acidiphilium sp. PM genome sequencing project

| PRJNA67947 | ENA

The PM microbiome

Project description:Microbial community of PM microbiome

| PRJEB19933 | ENA

Plasmodium falciparum PM X LC-MSMS

Project description:Plasmepsin X (PM X) is an aspartate protease expressed in the malaria parasie Plasmodium falciparum. Following synthesis PM X undergoes proteolytic processing. This project aims to understand the significance of PM X processing. To identify the cleavage sites, the processed PM X bands were excised from gels and subjected to LC-MSMS.

2022-10-14 | PXD035172 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data